利伐沙班与阿司匹林持续抗凝预防复发性VTE的医疗费用影响
基于EINSTEIN-CHOICE试验数据,从美国管理式医疗视角比较利伐沙班与阿司匹林持续抗凝的总医疗费用。利伐沙班10mg和20mg的每月每患者临床事件费用均低于阿司匹林,但总医疗费用更高;利伐沙班10mg降价15%后总费用低于阿司匹林。
要点
- 利伐沙班10mg和20mg的临床事件费用低于阿司匹林。
- 利伐沙班10mg总费用每月每患者高24美元,20mg高143美元。
- 利伐沙班10mg降价15%后总费用比阿司匹林低19美元。
核心结论
- 利伐沙班10mg和20mg与阿司匹林相比,临床事件费用更低但总医疗费用更高。
- 利伐沙班10mg降价15%后,总医疗费用低于阿司匹林。
研究设计与样本
- 基于EINSTEIN-CHOICE试验数据的费用分析,从美国管理式医疗视角计算总医疗费用(2016年美元)。
- 临床事件费用为事件率乘以护理成本,事件率来自EINSTEIN-CHOICE的1年Kaplan-Meier估计。
- 药物费用为批发 acquisition 成本乘以治疗时长,并进行单因素敏感性分析。
主要发现
- 每月每患者临床事件费用:利伐沙班10mg为123美元,利伐沙班20mg为243美元,阿司匹林为381美元。
- 与阿司匹林相比,利伐沙班10mg每月每患者总医疗费用高24美元,利伐沙班20mg高143美元。
- 利伐沙班10mg降价15%后,总医疗费用比阿司匹林低19美元。
临床怎么用
- 在考虑持续抗凝预防复发性VTE时,利伐沙班10mg降价15%可降低总医疗费用。
- 利伐沙班20mg在未降价时总医疗费用高于阿司匹林。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Using data from the Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) trial, this study assessed cost impact of continued anticoagulation therapy with rivaroxaban vs aspirin. METHODS: Total health-care costs (2016 USD) associated with rivaroxaban and aspirin were calculated as the sum of clinical event costs and drug costs from a US managed care perspective. Clinical event costs were calculated by multiplying event rate by cost of care. One-year Kaplan-Meier clinical event rates for recurrent pulmonary embolism, recurrent DVT, all-cause mortality, and bleeding were obtained from EINSTEIN-CHOICE. Cost of care was determined by literature review. Drug costs were the product of drug price (wholesale acquisition cost) and treatment duration. A one-way sensitivity analysis was conducted. RESULTS: Rivaroxaban users had lower per patient per month (PPPM) clinical event costs compared with aspirin users ($123, $243, and $381 for rivaroxaban 10 mg, rivaroxaban 20 mg, and aspirin, respectively). However, vs aspirin, PPPM total health-care costs were $24 higher for patients treated with rivaroxaban 10 mg ($143 higher for rivaroxaban 20 mg) due to higher cost of rivaroxaban. With a 15% discount for rivaroxaban 10 mg, the lower cost of clinical events for the rivaroxaban-treated patients more than fully offset the higher drug costs, and yielded a $19 lower total health-care cost. CONCLUSIONS: Continued therapy with rivaroxaban 10 and 20 mg vs aspirin was associated with lower clinical event costs but higher total health-care costs; with a 15% drug discount rivaroxaban 10 mg had lower total health-care costs than aspirin.
引用
- Wells PS, Prins MH, Beyer-Westendorf J, et al. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. Chest. 2018. PMID: 30201406. doi:10.1016/j.chest.2018.08.1059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。